Gufic Biosciences Limited
NSE: GUFICBIO BSE: GUFICBIO
NSE
397.10
-7.45 (-1.84%)
Prev Close
404.55
Open Price
402.6
Volume
123,432
Today Low / High
390.15 / 403.9
52 WK Low / High
298.8 / 504.25
Range
377 - 417
BSE
397.55
-7.10 (-1.75%)
Prev Close
404.65
Open Price
401.05
Volume
10,692
Today Low / High
389.05 / 402
52 WK Low / High
285 / 501.1
Range
378 - 417
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 397.1 (target range: 377 - 417), reflecting a change of -7.45 (-1.84155%). On the BSE, it is listed at 397.55 (target range: 378 - 417), showing a change of -7.1 (-1.7546%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
31 Jul
402.60
-1.37%
30 Jul
386.90
4.56%
29 Jul
387.10
-0.59%
28 Jul
387.15
-0.48%
25 Jul
386.20
0.25%
24 Jul
388.00
0.54%
23 Jul
379.65
2.42%
22 Jul
382.75
0.20%
21 Jul
380.70
0.56%
18 Jul
383.95
0.12%
17 Jul
380.95
1.18%
16 Jul
371.40
2.58%
15 Jul
354.50
4.77%
14 Jul
349.70
1.37%
11 Jul
348.05
0.29%
10 Jul
345.90
1.53%
09 Jul
340.25
1.37%
08 Jul
344.45
-1.22%
07 Jul
344.70
-0.07%
04 Jul
348.90
-0.96%
03 Jul
351.25
-0.67%
Gufic Biosciences Limited Graph
Gufic Biosciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gufic Biosciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 397.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 397.55 | 401.53 | 361.37 - 441.68 |
| 405.50 | 324.40 - 486.60 | ||
| 409.48 | 286.63 - 532.32 | ||
| Bearish Scenario | 397.55 | 393.57 | 354.22 - 432.93 |
| 389.60 | 311.68 - 467.52 | ||
| 385.62 | 269.94 - 501.31 |
Overview of Gufic Biosciences Limited
ISIN
INE742B01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
52,134
Market Cap
39,820,393,800
Last Dividend
0.1
Official Website
IPO Date
2004-10-19
DCF Diff
618.68
DCF
-248
Financial Ratios Every Investor Needs
Stock Dividend of GUFICBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-09-17 | September 17, 24 | 0.1 | 0.1 | 2024-09-18 | 2024-10-25 | |
| 2023-09-21 | September 21, 23 | 0.1 | 0.1 | 2023-09-21 | 2023-10-29 | |
| 2022-08-24 | August 24, 22 | 0.1 | 0.1 | 2022-08-25 | 2022-09-29 | |
| 2021-09-09 | September 09, 21 | 0.1 | 0.1 | 2021-09-13 | 2021-10-18 | |
| 2020-11-03 | November 03, 20 | 0.05 | 0.05 | 2020-11-04 | 2020-12-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 819.81 Cr | 522.82 Cr | 296.99 Cr | 0.3623 | 0.00 Cr | 0.00 Cr | 113.63 Cr | 69.65 Cr | 6.96 | 138.32 Cr | 0.0850 |
| 2024-03-31 | 806.67 Cr | 399.29 Cr | 407.37 Cr | 0.5050 | 5.44 Cr | 111.10 Cr | 289.38 Cr | 86.14 Cr | 8.74 | 148.05 Cr | 0.1068 |
| 2023-03-31 | 690.62 Cr | 485.38 Cr | 205.24 Cr | 0.2972 | 5.16 Cr | 14.90 Cr | 115.33 Cr | 79.70 Cr | 8.22 | 137.23 Cr | 0.1154 |
| 2022-03-31 | 779.16 Cr | 422.82 Cr | 356.34 Cr | 0.4573 | 4.43 Cr | 16.43 Cr | 129.10 Cr | 95.84 Cr | 9.89 | 148.49 Cr | 0.1230 |
| 2021-03-31 | 487.70 Cr | 256.51 Cr | 231.19 Cr | 0.4740 | 2.10 Cr | 9.20 Cr | 68.15 Cr | 44.23 Cr | 4.56 | 85.78 Cr | 0.0907 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.02 Cr | 1,169.36 Cr | 568.29 Cr | 601.0768 Cr | 336.19 Cr | 307.17 Cr | 216.87 Cr | 521.46 Cr | 0.00 Cr | 0.00 Cr | 11.74 Cr | 387.5572 Cr |
| 2024-03-31 | 1.14 Cr | 1,092.54 Cr | 559.98 Cr | 532.5605 Cr | 332.92 Cr | 331.78 Cr | 200.48 Cr | 474.17 Cr | 3.85 Cr | 0.00 Cr | 1.78 Cr | 372.0489 Cr |
| 2023-03-31 | 28.60 Cr | 861.16 Cr | 513.35 Cr | 347.8082 Cr | 334.19 Cr | 305.59 Cr | 183.46 Cr | 328.48 Cr | 5.36 Cr | 0.00 Cr | -0.18 Cr | 288.2075 Cr |
| 2022-03-31 | 11.61 Cr | 521.40 Cr | 252.28 Cr | 269.1180 Cr | 64.39 Cr | 52.78 Cr | 115.57 Cr | 155.43 Cr | -0.58 Cr | 5.00 Cr | 0.00 Cr | 186.4016 Cr |
| 2021-03-31 | 6.20 Cr | 392.06 Cr | 218.62 Cr | 173.4366 Cr | 61.54 Cr | 55.34 Cr | 94.40 Cr | 118.46 Cr | 2.83 Cr | 5.00 Cr | 0.01 Cr | 163.6624 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 102.6217 Cr | -71.7091 Cr | -16.3260 Cr | 27.0962 Cr | 0.0000 Cr | 29.0222 Cr | -75.5255 Cr | 69.6495 Cr | -6.7432 Cr | -1.0028 Cr | -16.3869 Cr |
| 2024-03-31 | -7.4571 Cr | -102.3889 Cr | 82.3810 Cr | -120.1516 Cr | -27.4651 Cr | 1.1368 Cr | -112.6945 Cr | 86.1356 Cr | 5.5070 Cr | -0.9720 Cr | -17.0246 Cr |
| 2023-03-31 | -26.5872 Cr | -190.7265 Cr | 234.3076 Cr | -214.1879 Cr | 16.9939 Cr | 28.6019 Cr | -187.6007 Cr | 79.7048 Cr | 250.0924 Cr | -1.0437 Cr | -67.8907 Cr |
| 2022-03-31 | 106.2395 Cr | -94.5891 Cr | -6.2437 Cr | 18.7864 Cr | 5.4067 Cr | 11.6081 Cr | -87.4531 Cr | 95.8401 Cr | 5.8934 Cr | -0.9211 Cr | -21.1623 Cr |
| 2021-03-31 | 87.2509 Cr | -6.6929 Cr | -78.6180 Cr | 74.8515 Cr | 1.9400 Cr | 6.2014 Cr | -12.3994 Cr | 44.2316 Cr | -61.3922 Cr | -0.3629 Cr | 28.0568 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 205.02 Cr | 133.09 Cr | 71.93 Cr | 0.3509 | 18.53 Cr | 7.72 Cr | 0.77 | 26.77 Cr | 0.0377 |
| 2024-12-31 | 207.79 Cr | 94.17 Cr | 113.63 Cr | 0.5468 | 29.31 Cr | 19.31 Cr | 1.93 | 35.79 Cr | 0.0929 |
| 2024-09-30 | 204.18 Cr | 96.13 Cr | 108.05 Cr | 0.5292 | 34.32 Cr | 21.77 Cr | 2.17 | 38.73 Cr | 0.1066 |
| 2024-06-30 | 202.81 Cr | 128.09 Cr | 74.72 Cr | 0.3684 | 31.47 Cr | 20.86 Cr | 2.08 | 37.03 Cr | 0.1028 |
| 2024-03-31 | 201.78 Cr | 130.08 Cr | 71.70 Cr | 0.3553 | 32.31 Cr | 20.05 Cr | 2.23 | 36.88 Cr | 0.0993 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.02 Cr | 0.00 Cr | 29.02 Cr | 314.93 Cr | 216.87 Cr | 624.52 Cr | 521.46 Cr | 1,169.36 Cr | 568.29 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 19.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -574.18 Cr |
| 2024-09-30 | 5.74 Cr | 13.66 Cr | 19.40 Cr | 0.00 Cr | 186.84 Cr | 578.39 Cr | 506.12 Cr | 1,104.67 Cr | 530.49 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 13.48 Cr | 0.00 Cr | 0.00 Cr | 13.48 Cr | 0.00 Cr | 0.00 Cr | -532.56 Cr |
| 2024-03-31 | 1.14 Cr | 8.87 Cr | 13.48 Cr | 317.59 Cr | 200.48 Cr | 600.48 Cr | 474.17 Cr | 1,092.54 Cr | 559.98 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 19.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 21.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 20.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 20.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 22.26 Cr | 8.28 Cr | 0.00 Cr | 0.00 Cr | 8.28 Cr | 24.60 Cr | 16.32 Cr | 0.00 Cr | 8.28 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,706.70 | ₹4,094,851,176,000.00 | ₹3,230,078.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,595.50 | ₹1,750,900,789,500.00 | ₹208,221.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,741.90 | ₹1,266,427,345,500.00 | ₹261,642.00 |
| Mankind Pharma Limited | MANKIND | ₹2,567.20 | ₹1,059,557,272,672.00 | ₹454,636.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,270.30 | ₹1,057,311,434,873.00 | ₹1,968,798.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹969.80 | ₹975,841,854,000.00 | ₹1,184,140.00 |
| Lupin Limited | LUPIN | ₹1,929.10 | ₹881,110,637,700.00 | ₹1,105,279.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,137.80 | ₹660,836,515,600.00 | ₹5,489,663.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,134.10 | ₹602,245,154,100.00 | ₹992,818.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,031.10 | ₹601,543,471,500.00 | ₹118,281.00 |
| Laurus Labs Limited | LAURUSLABS | ₹874.35 | ₹471,772,155,150.00 | ₹3,032,532.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹998.45 | ₹381,974,029,138.00 | ₹410,439.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,473.90 | ₹373,934,325,600.00 | ₹302,398.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,751.40 | ₹343,682,876,800.00 | ₹77,148.00 |
| Piramal Enterprises Limited | PEL | ₹1,251.80 | ₹283,755,520,400.00 | ₹2,308,743.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,769.30 | ₹276,573,437,400.00 | ₹284,299.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,667.50 | ₹270,933,732,500.00 | ₹282,417.00 |
| Eris Lifesciences Limited | ERIS | ₹1,798.90 | ₹245,004,783,300.00 | ₹52,393.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,186.00 | ₹229,650,000,000.00 | ₹15,858.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹977.90 | ₹192,218,957,700.00 | ₹54,884.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,194.10 | ₹190,197,442,100.00 | ₹370,820.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹953.40 | ₹170,763,474,000.00 | ₹430,795.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,281.00 | ₹170,393,901,900.00 | ₹72,413.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,066.40 | ₹157,070,576,880.00 | ₹60,750.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹474.90 | ₹115,231,635,600.00 | ₹940,401.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,918.50 | ₹98,243,548,900.00 | ₹6,998.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹888.25 | ₹86,862,766,925.00 | ₹105,636.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹911.20 | ₹82,586,265,744.00 | ₹287,584.00 |
| Strides Pharma Science Limited | STAR | ₹874.10 | ₹80,559,416,070.00 | ₹774,363.00 |
| FDC Limited | FDC | ₹479.35 | ₹78,042,973,500.00 | ₹94,963.00 |
| Suven Life Sciences Limited | SUVEN | ₹272.37 | ₹59,396,815,380.00 | ₹127,697.00 |
| Innova Captab Limited | INNOVACAP | ₹909.35 | ₹52,037,490,096.00 | ₹29,685.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹150.54 | ₹48,853,541,880.00 | ₹152,010.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹506.75 | ₹46,251,072,500.00 | ₹306,148.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹623.45 | ₹43,894,496,010.00 | ₹55,475.00 |
| Sequent Scientific Limited | SEQUENT | ₹171.97 | ₹43,050,109,950.00 | ₹363,036.00 |
| Hikal Limited | HIKAL | ₹323.10 | ₹39,838,553,100.00 | ₹170,616.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹397.10 | ₹39,820,393,800.00 | ₹123,432.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,401.00 | ₹39,710,139,000.00 | ₹24,441.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹740.40 | ₹37,552,421,640.00 | ₹56,665.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹58.45 | ₹32,027,911,300.00 | ₹1,497,181.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹641.85 | ₹30,907,003,050.00 | ₹88,498.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹103.16 | ₹30,280,245,320.00 | ₹5,353,453.00 |
| Indoco Remedies Limited | INDOCO | ₹317.85 | ₹29,320,995,015.00 | ₹63,895.00 |
| Alembic Limited | ALEMBICLTD | ₹112.12 | ₹28,790,397,728.00 | ₹257,904.00 |
Key Executives
Whole-Time Director
Mr. Pankaj Jayakumar Gandhi
Gender: male
Year Born: 1959
Chief Financial Officer
Mr. Devkinandan B. Roonghta
Gender: male
Year Born: 1965
Chairman & MD
Mr. Jayesh Pannalal Choksi
Gender: male
Year Born: 1954
President of Operation
Mr. Ashok Laxman Dev
Gender: male
Year Born:
Associate Vice President - Sales & Marketing
Mr. Pinak Padhya
Gender: male
Year Born:
Senior Vice President - Critical Care SBUs, Nepal & Institution
Mr. Shekhar Tarabir Aley
Gender: male
Year Born:
Chief Executive Officer & Whole Time Director
Mr. Pranav Jayesh Choksi
Gender: male
Year Born: 1983
Company Secretary, Compliance Officer & Legal Manager
Ms. Ami Naresh Shah
Gender: female
Year Born:
Chief Operating Officer
Mr. Nagesh Yarrabathina
Gender: male
Year Born:
Head Human Resource Department
Mr. Sunil Desai
Gender: male
Year Born:
FAQs about Gufic Biosciences Limited
Who is the CEO of the company?
The CEO is Pranav Jayesh Choksi.
What is the current market price of the stock?
The current price is ₹397.10.
What is the 52-week price range?
The range is ₹298.8-504.25.
What is the market capitalization of the company?
The market capitalization is ₹3,982.04 crores.
What is the dividend yield?
The dividend yield is 0.03%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 57.13.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Gufic Biosciences Limited (ISIN: INE742B01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,982.04 crores and an average daily volume of 52,134 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.1.